“It’s just hair loss,” doesn’t adequately describe the significant impact alopecia areata has on a patient’s appearance and self-esteem. The visible nature of the disease can lead to psychosocial effects such as stress, anxiety, depression, and social isolation. In this interactive, case-based activity, Brett King, MD, PhD, and Natasha Mesinkovska, MD, PhD, share their real-world experience treating patients with alopecia areata. They discuss the higher prevalence of alopecia areata in persons of color, psychological effects of the disease, diagnosis, and treatment approaches. Additionally, the efficacy, safety, and monitoring of JAK inhibitors are compared to other immunosuppressants, along with shared decision-making approaches, to provide patient-centered care.
Course Credit:
1.00 AAPA Category I CME Credit
1.00 ACPE Contact Hour
1.00 AMA PRA Category 1 CreditTM
1.00 ANCC Contact Hour
1.00 CA-BRN Contact Hour
0.08 Pharmacology Hours
Dates:
Opens: 2025-03-27
Closes: 2026-03-27
Target Audience:
This activity was developed for dermatologists, pediatric dermatologists, dermatology nurse practitioners and dermatology physician associates, and other clinicians involved in the management of patients diagnosed with alopecia areata.
This activity is supported by an educational grant from Pfizer Inc.
Accreditation
The Annenberg Center for Health Sciences at Eisenhower designates this enduring activity for a maximum of 1 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Annenberg Center for Health Sciences at Eisenhower designates this knowledge-based activity for a maximum of 1 hour . Credit will be provided to NABP CPE Monitor within 60 days after the activity completion.
Annenberg Center for Health Sciences at Eisenhower designates this enduring activity for a maximum of 1 ANCC contact hour, including 0.08 pharmacology hours.
To receive credit for education contact hours outside of the state of California, please check with your state board of registered nursing for reciprocity.
Additional Content Planners
Eugene Cullen, MD (Peer Reviewer)No significant relationships to disclose.
Tim Drake, PharmD, MBA, BCPS (Medical Writer)
No significant relationships to disclose.
Amber Lambert, MSN, FNP-C, DNP (Nurse Reviewer)
No significant relationships to disclose.
Annenberg Center for Health Sciences
Staff at the Annenberg Center for Health Sciences at Eisenhower have no relevant financial relationships to disclose.
All of the financial relationships listed for these individuals have been mitigated.
-
Brett King, MD, PhD
Associate Professor of Dermatology
Yale School of Medicine
New Haven, Connecticut -
Natasha A. Mesinkovska, MD, PhD
Associate Professor, Dermatology
UC Irvine School of Medicine
Irvine, California
Presenting Faculty
Learning Objectives
- Describe the epidemiology of AA in persons of color
- Collaborate with the patient to develop a treatment plan to provide therapy to meet the goals of the persons of color with AA
- Incorporate tools into clinical practice to classify the severity of AA and monitor disease progression
- Recite the major warnings associated with the use of JAK inhibitors
Faculty Disclosures
Brett King, MD, PhD
Advisory Board and Consultant: AbbVie, Almirall, AltruBio, Inc., Amgen, AnaptysBio, Apogee Therapeutics, Aquestive, Arena Pharmaceuticals, Aslan Pharmaceuticals, Bristol Meyers Squibb, Concert Pharmaceuticals Inc., Equillium, GSK, Horizon Therapeutics, Incyte Corp, Janssen Pharmaceuticals, LEO Pharma, Lilly, Merck, Otsuka Pharmaceutical, Pfizer Inc, Q32 Bio Inc., Regeneron, Sanofi Genzyme, Soterios, Sun Pharmaceuticals, Takeda, TWi Biotechnology, Inc.
Natasha A. Mesinkovska, MD, PhD
Advisory Board: AbbVie, Almirall, Galderma, Johnson & Johnson, Lilly, Merck, Pfizer, Sun Pharmaceuticals
Speakers Bureau: Lilly, Pfizer